Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Safety of a Potential New Drug in Comparison to the Standard Practice of Dosing With Warfarin for Non-valvular Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female, 18 to 80 years old.~2. Able to provide written informed consent.~3. Persistent non-valvular AF supported by abnormal electrocardiogram (ECG)~4. A congestive heart failure, hypertension, age ≥ 75 years, diabetes, and prior stroke (CHADS2) index score of at least 2~Exclusion Criteria:~1. Subjects with mitral valve disease or previous valvular heart surgery~2. Known contraindication to any anticoagulant including vitamin K antagonists such as warfarin~3. Known or suspected hereditary or acquired bleeding or coagulation disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): DU-176b 30mg tablet once daily
- 2 (Type: EXPERIMENTAL): DU-176b 60mg once daily
- 3 (Type: EXPERIMENTAL): DU-176b 30mg b.i.d.
- 4 (Type: EXPERIMENTAL): DU-176b 60mg tablets two times a day
- 5 (Type: ACTIVE_COMPARATOR): warfarin tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).